Editas Medicine, Inc.
NASDAQ:EDITBiotechnology
+$0.07 today
- Market cap
- $273.18M
- Beta
- 2.10
- P/E (TTM)
- -2.4
- EPS (TTM)
- -$1.11
Volume 1.99M
Average 2.06M
EDIT Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Editas Medicine, Inc.NASDAQ: EDIT
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $10.23M fell 23.5% year over year, ahead of the -29.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 9.9% from the prior quarter. Over 3 fiscal years it compounded at -11.0% a year.
Context
- Selling, general & admin amounted to 123.2% of revenue in FY2025, down 99.6 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 8 analysts of $69.85M (+40.0%) for the fiscal year ending Dec 2026, a step up from the -30.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $10.23M-9.9% QoQ
- Last fiscal yearDec 2025
- $49.9M-30.7% YoY
- LTMMar 2026
- $46.76M-29.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 49.9M USD
- Year-over-year change
- -30.7%
- 4-year CAGR
- -10.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 49.9M | -30.7% |
| FY2024 | 2024-12-31 | 71.99M | +3.4% |
| FY2023 | 2023-12-31 | 69.65M | -1.5% |
| FY2022 | 2022-12-31 | 70.7M | -7.2% |
| FY2021 | 2021-12-31 | 76.18M | — |
Selling, General & Admin vs competitors
How EDIT compares with its peers on the latest reported figures
- EDIT's LTM Mar 2026 selling, general & admin of $46.76M is the 6th highest of the 9 companies compared; the peer median is $62.68M.
- Its year-over-year change of -29.2% is the 8th highest of 9, against a peer median of +3.3%.
- Selling, general & admin amounts to 120.9% of revenue for EDIT, versus a peer median of 256.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $157.94M | +14.5% | +9.9% | 239.0% | |
| LTM Jun 2026 | $125.4M | +14.0% | +9.0% | 80.4% | |
| LTM Mar 2026 | $75.11M | -30.1% | +13.7% | — | |
| LTM Sep 2026 | $68.9M | -6.0% | -10.5% | 273.7% | |
| LTM Mar 2026 | $56.47M | +8.0% | +20.6% | 1399.8% | |
| LTM Mar 2026 | $46.76M | -29.2% | -11.0% | 120.9% | |
| LTM Mar 2026 | $36.25M | -1.5% | -0.1% | 323.5% | |
| LTM Mar 2026 | $34.74M | +87.8% | +52.2% | — | |
| LTM Mar 2026 | $30.49M | -13.9% | -7.9% | 67.6% | |
SCTXScribe Therapeutics Inc. | — | — | — | — | — |
| Peer median (excluding EDIT) | $62.68M | +3.3% | +9.5% | 256.3% | |
Competitors are the stored peer set for EDIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 25.54M | 19.71M | 78.12M | 32.31M | 40.52M |
| Cost of Revenue | 5.05M | 6.34M | 6.06M | 199.25M | 0 |
| Gross Profit | 20.49M | 13.38M | 72.06M | (166.93M) | 40.52M |
| Gross Margin | 80.2% | 67.9% | 92.2% | -516.6% | 100.0% |
| Research & Development | 142.51M | 174.96M | 177.65M | 199.25M | 89.95M |
| Selling, General & Admin | 76.18M | 70.7M | 69.65M | 71.99M | 49.9M |
| Operating Expenses | 213.64M | 239.33M | 241.24M | 84.22M | 139.86M |
| Depreciation & Amortization | 5.05M | 6.34M | 6.06M | 5.81M | 5.28M |
| EBITDA | (187.45M) | (214.1M) | (147.16M) | (233.11M) | (148.61M) |
| EBITDA Margin | -733.8% | -1086.1% | -188.4% | -721.4% | -366.8% |
| Operating Income | (193.15M) | (225.95M) | (169.18M) | (251.15M) | (99.34M) |
| Operating Margin | -756.1% | -1146.3% | -216.6% | -777.2% | -245.2% |
| Interest Income | 607K | 5.52M | 17.57M | 14.06M | 8.31M |
| Interest Expense | 0 | 0 | 0 | 0 | 6.17M |
| Other Income / Expenses | 644K | 5.52M | 15.96M | 14.06M | (60.72M) |
| Income Before Tax | (192.5M) | (220.43M) | (153.22M) | (237.09M) | (160.06M) |
| Pre-Tax Margin | -753.6% | -1118.3% | -196.1% | -733.7% | -395.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (192.5M) | (220.43M) | (153.22M) | (237.09M) | (160.06M) |
| Net Margin | -753.6% | -1118.3% | -196.1% | -733.7% | -395.0% |
| EPS (Basic) | (2.85) | (3.21) | (2.02) | (2.88) | (1.80) |
| EPS (Diluted) | (2.85) | (3.21) | (2.02) | (2.88) | (1.80) |
| Weighted Avg Shares | 67.62M | 68.66M | 75.97M | 82.34M | 88.75M |
| Weighted Avg Shares (Diluted) | 67.62M | 68.66M | 75.97M | 82.34M | 88.75M |
Editas Medicine, Inc.
NASDAQ:EDIT
Intrinsic Alpha fair value
Locked
Current Price
$1.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.